What Drives This Biotech’s Business Model?
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing prescription medicines. The business is built around a relatively concentrated set of therapies, with revenue tied to ongoing patient use rather than one-off transactions. It operates at large scale for a biotech, with a market value of about USD 111.4 billion, placing it among the sector’s heavyweights. The company’s profile combines high-margin products with a balance sheet that is meaningfully cash-backed.
Are Margins and Cash Flow Holding Up?
FundamentalsFor 2025, reported in USD, revenue was USD 12.0 billion, up 8.9% versus the prior year. The cost structure shows unusually wide trailing margins, including an 86.24% gross margin, a 34.77% operating margin, and a 32.94% net profit margin.
Cash on hand was USD 5.1 billion at year-end, with depreciation and amortization of USD 209.8 million. On trailing metrics, the business also posted 22.70% ROE, and the stock’s beta of 0.37 indicates relatively muted price swings versus the broader market.
Is the Market Underestimating Fair Value?
DCF / MultiplesAt USD 438.71, the stock sits above the lower fair-value estimate of USD 350.77, below the central value of USD 607.67, and well under the upper estimate of USD 975.49. That range is paired with a 28.10 P/E and 23.88 EV/EBITDA, reflecting a valuation that prices in the persistence implied by the current margin structure.
Still Priced Below Its Strength
TakeawayThe price doesn’t look like it fully trusts the durability. That skepticism is notable given the margin profile and cash. The case works if revenue keeps compounding without margin erosion. It breaks if profitability normalizes faster than expected. Overall, this still looks like a mispricing to the low side.